FDA Plans To Require Submission Of Overseas Label Changes Under Draft Rule

FDA is developing a proposed rule that would require pharmaceutical manufacturers to notify the agency of labeling changes that occur overseas, FDA Office of Drug Evaluation V Deputy Director Jonca Bull, MD, indicated during a Dec. 5 House Government Reform Committee hearing.